Technetium Tetrofosmin

CHEMBL2110566 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Technetium tetrofosmin is the parent diphosphine ligand formulation radiolabeled with technetium-99m for myocardial perfusion SPECT imaging. See technetium-tc-99m-tetrofosmin for complete pharmacological details. It is used in stress and rest myocardial perfusion imaging for coronary artery disease diagnosis and risk stratification.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Technetium tetrofosmin is the parent diphosphine ligand formulation radiolabeled with technetium-99m for myocardial perfusion SPECT imaging. See technetium-tc-99m-tetrofosmin for complete pharmacological details. It is used in stress and rest myocardial perfusion imaging for coronary artery disease diagnosis and risk stratification.

Yes, Technetium Tetrofosmin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110566. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.